Psoriatic Arthritis

The survey found 42% of patients with psoriatic disease had never discussed treatment goals with their provider, and less than half of patients with psoriatic arthritis were treated by a rheumatologist.

ACR20 response was significantly higher in patients receiving either deucravacitinib 6 mg daily or 12 mg daily when compared with placebo.

Patients treated with ixekizumab had higher rates of simultaneous complete skin and nail clearance compared with etanercept, ustekinumab and adalimumab.

Furthermore, psoriatic treatment did not appear to significantly reduce COVID-19 vaccine efficacy.

Patients with psoriatic arthritis and ankylosing spondylitis experienced rapid pain reduction with upadacitinib, regardless of treatment history.

John Tesser, MD, closes the discussion with unmet needs in the PsA treatment landscape, as well as what he hopes to see in the future.

Expert panelists share tips for boosting patient compliance among patients with psoriatic arthritis.

Three colleagues share insights into their evolving approaches regarding the management of patients with psoriatic arthritis who test positive for COVID-19.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, emphasize the important of vaccination against COVID-19 for patients with psoriatic arthritis.

A panel of experts and colleagues recall the indicators and steps that need to be taken when changing PsA therapies.

“Incorporating patient perspectives will not only help better tailor therapies in this heterogeneous population but also identify treatment targets that are relevant to the individual patients," investigators explained.

Three experts discuss measurement of outcomes for psoriatic arthritis management and what a “successful” treatment looks like.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, profile classes of interleukin inhibitors and the potential benefits for patients with psoriatic arthritis.

Soumya D. Chakravarty, MD, PhD, discusses the growing body of clinical evidence evaluating joint efficacy, safety, and patient-reported outcomes in patients with psoriatic arthritis receiving guselkumab.

Free or total 25(OH)D serum levels were not associated with psoriasis disease severity in this small study of biologic-naïve patients.

Before closing out their discussion on psoriatic arthritis management, two experts consider how the COVID-19 pandemic has affected their practice.

Roy Fleischmann, MD, discusses the usage of biosimilars in the United States and hypothesizes about what is in store for the future.

The panel explains the many conventional DMARDs that can be used to treat psoriatic arthritis, as well as their role in management.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, talk about the importance of shared decision-making in the treatment of psoriatic arthritis.

Thought leaders discuss differences in recommendations between guidelines for the management of psoriatic arthritis.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, discuss the common triggers patients with psoriatic arthritis and the importance of stress management.

In this Q&A, Krzysztof Bonek, MD, PhD, discussed the findings of his study that looked at the associations of IL-18 serum levels with serum lipids, cardiovascular risk and disease activity in patients with ankylosing spondylitis and psoriatic arthritis.

Shared insight on technical processes and protocols used to manage patients with psoriatic arthritis, including those for prescription fulfillment.

A brief overview on the drivers of noncompliance and treatment adherence in patients with psoriatic arthritis.

Rheumatology Network interviewed Jeffrey Stark, MD, to discuss the BE COMPLETE study, which examined the efficacy of bimekizumab for treating psoriatic arthritis.